GlaxoSmithKline (LON:GSK) Rating Increased to Buy at Beaufort Securities
https://ledgergazette.com/2018/03/03/glaxosmithkline-gsk-raised-to-buy-at-beaufort-securities.html
GlaxoSmithKline (LON:GSK) was upgraded by equities research analysts at Beaufort Securities to a “buy” rating in a report released on Thursday, February 8th. The brokerage currently has a GBX 1,500 ($20.72) target price on the stock, up from their prior target price of GBX 1,450 ($20.03). GlaxoSmithKline has an average rating of “Hold” and a consensus price target of GBX 1,538.18 ($21.25). Goldman Sachs Group reaffirmed a “buy” rating and issued a GBX 1,900 ($26.25) target price on shares of GlaxoSmithKline in a research note on Tuesday, October 17th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the company.
GlaxoSmithKline plc (LON:GSK): Has Recent Earnings Growth Beaten Long-Term Trend?
https://simplywall.st/stocks/gb/pharmaceuticals-biotech/lse-gsk/glaxosmithkline-shares/news/glaxosmithkline-plc-longsk-has-recent-earnings-growth-beaten-long-term-trend/
Revenue growth over the last couple of years, has been positive, nevertheless earnings growth has been falling. There could be variables that are impacting the entire industry hence the high industry growth rate over the same time frame. For GlaxoSmithKline, its most recent earnings (trailing twelve month) is UK£1.53B, which, in comparison to the prior year’s figure, has moved up by an impressive 67.98%. When GlaxoSmithKline plc (LSE:GSK) announced its most recent earnings (31 December 2017), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. This implies that GlaxoSmithKline has been increasing expenses, which is harming margins and earnings, and is not a sustainable practice.
Should You Buy GlaxoSmithKline plc (LON:GSK) Now?
https://simplywall.st/stocks/gb/pharmaceuticals-biotech/lse-gsk/glaxosmithkline-shares/news/should-you-buy-glaxosmithkline-plc-longsk-now/
It’s trading around 7.91% below my intrinsic value, which means if you buy GlaxoSmithKline today, you’d be paying a fair price for it. But is this actually reflective of the share value of the large-cap? The company’s stock saw its share price hover around a small range of £12.43 to £13.64 over the last few weeks. If you’ve been keeping tabs on GSK, now may not be the most optimal time to buy, given it is trading around its fair value. GSK’s optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value.
GlaxoSmithKline (GSK) Releases Earnings Results, Beats Expectations By $0.90 EPS
https://ledgergazette.com/2018/03/03/glaxosmithkline-gsk-releases-quarterly-earnings-results-beats-estimates-by-0-90-eps.html
In the last quarter, insiders have bought 590 shares of company stock valued at $754,966 and have sold 43,765 shares valued at $57,352,709. The company reported GBX 111.80 ($1.54) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of GBX 110.90 ($1.53) by GBX 0.90 ($0.01), reports. Citigroup reiterated a “neutral” rating and issued a GBX 1,400 ($19.34) target price on shares of GlaxoSmithKline in a research report on Wednesday, December 13th. The stock presently has an average rating of “Hold” and an average price target of GBX 1,538.18 ($21.25). Morgan Stanley set a GBX 1,450 ($20.03) target price on GlaxoSmithKline and gave the stock a “sell” rating in a research report on Monday, November 6th.
